Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with bundibugyo ebolavirus

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 3, 2011, Pages

  Falzarano, Darryl ^a,b,c   Feldmann, Friederike ^a,c   Grolla, Allen ^a   Leung, Anders ^a   Ebihara, Hideki ^a,c   Strong, James E ^a,b   Marzi, Andrea ^a,c   Takada, Ayato ^d   Jones, Shane ^a   Gren, Jason ^a   Geisbert, Joan ^e   Jones, Steven M ^a,b   Geisbert, Thomas W ^e   Feldmann, Heinz ^a,b,c  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d HOKKAIDO UNIVERSITY   (Japan)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BUNDIBUGYO EBOLAVIRUS; CONTROLLED STUDY; COTE D'IVOIRE EBOLAVIRUS; CROSS REACTION; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EPIDEMIC; FEMALE; MACACA; NONHUMAN; PHYLOGENY; PILOT STUDY; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE; UGANDA; VACCINATION; VESICULAR STOMATITIS VIRUS; VIRUS RECOMBINANT; VIRUS STRAIN; ZAIRE EBOLAVIRUS;

ANIMALS; ANTIBODIES, VIRAL; EBOLA VACCINES; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; MACACA FASCICULARIS; MALE; PILOT PROJECTS; SPECIES SPECIFICITY; VACCINES, SYNTHETIC; VESICULOVIRUS;

EID: 80054742592     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir350     Document Type: Article

References (30)

1. Feldmann H, Geisbert T, Jahrling P, et al. Filoviridae. In Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA eds: Virus taxonomy: VIIIth report of the International Committee on the Taxonomy of Viruses. San Diego, CA: Elsevier, 2005: 645-53.
2. Bray M, Geisbert TW. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 2005; 37:1560-6. (Pubitemid 40719635)
3. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2010; 377:849-62.
4. Gonzalez JP, Pourrut X, Leroy E. Ebolavirus and other filoviruses. Curr Top Microbiol Immunol 2007; 315:363-87.
5. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424:681-4. (Pubitemid 36987993)
6. Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007; 81:6379-88. (Pubitemid 46878044)
7. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90. (Pubitemid 41021212)
8. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, et al. Crossprotection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 2006; 80:9659-6.
9. Geisbert TW, Bausch DG, Feldmann H. Prospects for immunization against Marburg and Ebola viruses. Rev Med Virol 2010; 20:344-57.
10. Swenson DL, Wang D, Luo M, et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 2008; 15:460-7. (Pubitemid 351967082)
11. Riemenschneider J, Garrison A, Geisbert J, et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 2003; 21:4071-80. (Pubitemid 37345136)
12. Geisbert TW, Feldmann H. Vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 2011.
13. Pratt WD, Wang D, Nichols DK, et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 2010; 17:572-81.
14. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006; 3:e177.
15. Towner JS, Sealy TK, Khristova ML, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008; 4:e1000212.
16. Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol 2009; 83:7296-304.
17. Hensley LE, Mulangu S, Asiedu C, et al. Demonstration of crossprotective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog 2010; 6:e1000904.
18. Kuhn JH, Becker S, Ebihara H, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 2010; 155:2083-103.
19. Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005; 438:575-6. (Pubitemid 41740557)
20. Towner JS, Pourrut X, Albarino CG, et al. Marburg virus infection detected in a common African bat. PLoS One 2007; 2:e764.
21. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, AmanMJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005; 23:3033-42. (Pubitemid 40462443)
22. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replicationcompetent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78:5458-65. (Pubitemid 38581495)
23. Marzi A, Ebihara H, Callison J, et al. Vesicular stomatitis virus based Ebola vaccines with improved cross-protective efficacy. J Infect Dis 2011 in press, Filovirus supplement.
24. Nakayama E, Yokoyama A, Miyamoto H, et al. Enzyme-linked immunosorbent assay for the detection of filovirus species-specific antibodies. Clin Vaccine Immunol 2010; 17:1723-28.
25. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008; 26:6894-900.
26. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008; 4:e1000225.
27. Qiu X, Fernando L, Alimonti JB, et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One 2009; 4:e5547.
28. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol 2003; 77:7539-44. (Pubitemid 36734524)
29. Takada A, Watanabe S, Okazaki K, Kida H, Kawaoka Y. Infectivityenhancing antibodies to Ebola virus glycoprotein. J Virol 2001; 75:2324-30. (Pubitemid 32147570)
30. Gupta M, Goldsmith CS, Metcalfe MG, Spiropoulou CF, Rollin PE. Reduced virus replication, proinflammatory cytokine production, and delayed macrophage cell death in human PBMCs infected with the newly discovered Bundibugyo ebolavirus relative to Zaire ebolavirus. Virology 2010; 402:203-8.